Coloplast has successfully raised approximately DKK 9.2bn through issue of 12.2 million new B shares in a directed issue and private placement completed through an accelerated book-building process consisting of new B shares to be admitted to trading and official listing on Nasdaq Copenhagen.
The offering of new B shares was carried out as a private placement to qualified institutional and other professional investors in Denmark and in certain other jurisdictions as well as certain other persons at market price without pre-emption rights for Coloplast’s existing shareholders.
On 7 July 2023, Coloplast announced an agreement to acquire the company Kerecis for a consideration of up to USD 1.3bn (around DKK 8.9bn). The net proceeds from completion of the offering of new B shares are intended to be used for payment of the purchase price in respect of the transaction with Kerecis.
Coloplast develops and manufactures intimate health care products that make life easier for people with private medical conditions. Coloplast was founded in 1957 and is today a globally leading provider of intimate health care services across its divisions Chronic Care, Wound & Skin Care, Interventional Urology, and Voice and Respiratory Care.
Danske Bank A/S acted as Global Coordinator in connection with the offering and together with Nordea Danmark, Filial af Nordea Bank Abp, Finland, Jefferies GmbH and Morgan Stanley & Co International plc as Joint Bookrunners in connection with the offering.
Accura acted as Danish legal advisor to the Joint Bookrunners in connection with the transaction.
Photo: Coloplast